Bayer takes giant colon on tour to spur colorectal cancer talk by Carly Helfand Thursday, May 10, 2018 Bayer is taking a giant colon on tour. Yes, you read that right.
Bayer's growth-driving quintet? Better make that a trio by Angus Liu Thursday, May 3, 2018 A strong euro doesn't explain away Bayer's consumer health stall—or the low turnout for key cancer meds Xofigo and Stivarga.
Lilly's Cyramza rallies back in liver cancer with biomarker win by Carly Helfand Wednesday, April 4, 2018 After Lilly’s Cyramza flopped a liver cancer trial in 2014, the company designed a trial for a specific subpopulation. Now, it’s back with a win.
Merck's Keytruda makes headway in hard-to-treat liver cancer by Carly Helfand Tuesday, January 23, 2018 Kidney cancer isn’t the only disease area where Merck’s Keytruda is moving in to challenge Bristol-Myers Squibb’s Opdivo.
NICE shoots down Bayer's Stivarga in liver cancer by Carly Helfand Wednesday, November 8, 2017 Bayer is working to position Stivarga as part of a liver cancer treatment regimen, But that’s not going to work in England. At least, not yet.
NICE expands Bayer's Stivarga prospects with move from CDF by Carly Helfand Thursday, October 12, 2017 Since NICE took the reins of England’s Cancer Drugs Fund last year, several drugmakers have seen their meds get the boot. Not Bayer.
Bristol's Opdivo steps up to challenge Bayer in liver cancer by Carly Helfand Monday, September 25, 2017 With its latest FDA nod, Bristol-Myers Squibb’s Opdivo won the right to take on Bayer's Stivaga in liver cancer.
ASCO: Eisai's Lenvima nabs survival edge over Nexavar by Carly Helfand Sunday, June 4, 2017 Bayer's Nexavar has had the first-line liver cancer space to itself for years, but Eisai is doing its best to change that.
BMS, leading I-O in liver cancer, nabs Opdivo 'priority' tag by Carly Helfand Thursday, May 25, 2017 In the immuno-oncology rivalry between Merck’s Keytruda and BMS’ Opdivo, Keytruda has been running the table. But Opdivo boasts the latest win.
